RT Journal Article
SR Electronic
T1 Magnitude and kinetics of anti-SARS-CoV-2 antibody responses and their relationship to disease severity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.03.20121525
DO 10.1101/2020.06.03.20121525
A1 Lynch, Kara L
A1 Whitman, Jeffrey D
A1 Lacanienta, Noreen P
A1 Beckerdite, Erica W
A1 Kastner, Shannon A
A1 Shy, Brian R
A1 Goldgof, Gregory M
A1 Levine, Andrew G
A1 Bapat, Sagar P
A1 Stramer, Susan L
A1 Esensten, Jonathan H
A1 Hightower, Allen W
A1 Bern, Caryn
A1 Wu, Alan HB
YR 2020
UL http://medrxiv.org/content/early/2020/06/09/2020.06.03.20121525.abstract
AB Background SARS-CoV-2 infection can be detected indirectly by measuring the host immune response. Anti-viral antibody concentrations generally correlate with host protection and viral neutralization, but in rare cases, antibodies can promote disease progression. Elucidation of the kinetics and magnitude of the SARS-CoV-2 antibody response is essential to understand the pathogenesis of COVID-19 and identify potential therapeutic targets.Methods Sera (n=533) from patients with RT-PCR confirmed COVID-19 (n=153) were tested using a high-throughput quantitative IgM and IgG assay that detects antibodies to the spike protein receptor binding domain and nucleocapsid protein. Individual and serial samples covered the time of initial diagnosis, during the disease course, and following recovery. We evaluated antibody kinetics and correlation between magnitude of the response and disease severity.Results Patterns of SARS-CoV-2 antibody production varied considerably. Among 52 patients with 3 or more serial specimens, 44 (84.6%) and 42 (80.8%) had observed IgM and IgG seroconversion at a median of 8 and 10 days, respectively. Compared to those with milder disease, peak measurements were significantly higher for patients admitted to the intensive care unit for all time intervals between 6 and 20 days for IgM, and all intervals after 5 days for IgG.Conclusions High sensitivity assays with a robust dynamic range provide a comprehensive picture of host antibody response to SARS-CoV-2. IgM and IgG responses were significantly higher in patients with severe than mild disease. These differences may affect strategies for seroprevalence studies, therapeutics and vaccine development.Competing Interest StatementAHBW is on the scientific advisory board for ET Healthcare. All other authors declare no competing interests.Funding StatementThe study was funded by departmental discretionary funds available to the corresponding author. Reagents were donated by ET Healthcare, Inc. ET Healthcare was not involved in any aspect of the study design or execution and did not review the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Two separate protocols, one for Zuckerberg San Francisco General Hospital (ZSFG) remnant specimens (IRB #20-30387) and the other for convalescent plasma donor screening (IRB #20-30637), were approved by the Institutional Review Board of the University of California, San Francisco. The committee judged that written consent was not required for use of remnant specimens. Written informed consent was obtained for convalescent plasma donor screening.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data can be made available via request to the corresponding author.